Literature DB >> 19046932

Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.

P Burra1, M Senzolo, A Masier, H Prestele, R Jones, D Samuel, F Villamil.   

Abstract

INTRODUCTION: Renal failure, both acute and chronic, is a common complication after liver transplantation and can seriously jeopardise long-term outcome. Given organ shortage it should be essential to determine which patients will experience progressive and severe renal dysfunction after liver transplantation (LT). AIM: To correlate pre-transplant renal function and risk factors for renal failure after liver transplantation with occurrence of renal failure at 1 and 5 years after LT, with particular attention to hepatitis C virus (HCV) infection.
METHODS: Data from patients enrolled in the liver section of Neoral MOST (Multinational Observational Study in Transplantation) study were used for the analysis. HCV status, pre-transplant serum creatinine level, recipient gender, recipient age, pre-transplant arterial hypertension, pre-transplant diabetes mellitus, pre-transplant antiviral therapy, the time of the transplant (before or after 2000) and immunosuppressive regimen were collected for each patient. Post-transplant occurrence of renal failure at 1 and 5 years was defined as a GFR<60 mL/min/1.73 m(2) (Stage III of the National Kidney Foundation).
RESULTS: Data from 1948 patients enrolled in the study were considered. Glomerular filtration rate (GFR) was evaluated in 406 patients at 1 year and in 233 patients at 5 years after LT. The prevalence of HCV infection was 35% in the former and 37% in the latter. The median GFR was 70 mL/min/1.73 m(2) after 1 year and 69 mL/min after 5 years, significantly lower in HCV-positive (HCV+) than in HCV-negative (HCV-) patients both 1 and 5 years after LT (p<0.001). GFR before transplant correlated with GFR at 1 month, 1 and 3 years (p<0.0001 for all correlations). Multivariate analysis confirmed HCV status, pre-LT serum creatinine levels and recipient gender as significant predictors of 1-year GFR (p<0.001 for all three). Further analysis of the effect of recipient gender indicated that the only significant risk factor observed in both male and female patients was HCV positivity. Only 1-year GFR was an independent predictor of 5-year GFR (p<0.001). HCV+ status, cyclosporine (CsA) exposure, antiviral therapy and diabetes mellitus had no significant influence on 5-year GFR.
CONCLUSIONS: HCV status and pre-LT serum creatinine levels were independent predictors of renal function a year after LT, together with GFR before transplant. The negative impact of HCV positivity on renal function was not confirmed in the long term, whereas the prognostic influence of an abnormal renal function in the early post-transplant period was more persistent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19046932     DOI: 10.1016/j.dld.2008.09.018

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  18 in total

1.  Early Postoperative Neutrophil Gelatinase-Associated Lipocalin Predicts the Development of Chronic Kidney Disease After Liver Transplantation.

Authors:  Giuseppe Cullaro; Joseph F Pisa; Robert S Brown; Gebhard Wagener; Elizabeth C Verna
Journal:  Transplantation       Date:  2018-05       Impact factor: 4.939

2.  The effect of kidney diseases on survival in liver transplant patients.

Authors:  Inci Süleymanlar; Vural Taner Yılmaz; Hüseyin Koçak; Ayhan Dinçkan; Alihan Gürkan; Fevzi Ersoy; Gültekin Süleymanlar
Journal:  Int Urol Nephrol       Date:  2010-08-05       Impact factor: 2.370

3.  Underestimation of chronic renal dysfunction after liver transplantation: ICEBERG study.

Authors:  Evaristo Varo; Rafael Bañares; Magda Guilera
Journal:  World J Transplant       Date:  2015-03-24

Review 4.  Pre-transplant kidney function predicts chronic kidney disease after liver transplant: meta-analysis of observational studies.

Authors:  Fabrizio Fabrizi; Vivek Dixit; Paul Martin; Piergiorgio Messa
Journal:  Dig Dis Sci       Date:  2011-01-08       Impact factor: 3.199

5.  Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate.

Authors:  Alina M Allen; W Ray Kim; Terry M Therneau; Joseph J Larson; Julie K Heimbach; Andrew D Rule
Journal:  J Hepatol       Date:  2014-04-05       Impact factor: 25.083

Review 6.  Female gender in the setting of liver transplantation.

Authors:  Kryssia Isabel Rodríguez-Castro; Eleonora De Martin; Martina Gambato; Silvia Lazzaro; Erica Villa; Patrizia Burra
Journal:  World J Transplant       Date:  2014-12-24

7.  Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010.

Authors:  Zhenhua Hu; Jie Zhou; Haibo Wang; Min Zhang; Shaogang Li; Yuzhou Huang; Jian Wu; Zhiwei Li; Lin Zhou; Shusen Zheng
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

8.  Risk factors for early viral infections after liver transplantation.

Authors:  Cornelius Johannes Busch; Benedikt Hermann Siegler; Heike Werle; Christoph Lichtenstern; Thomas Bruckner; Alexandra Heininger; Arianeb Mehrabi; Karl Heinz Weiss; Markus Alexander Weigand; Marcel Hochreiter
Journal:  Langenbecks Arch Surg       Date:  2018-04-25       Impact factor: 3.445

Review 9.  Long-term Management of the Adult Liver Transplantation Recipients.

Authors:  Narendra S Choudhary; Neeraj Saraf; Sanjiv Saigal; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2020-07-02

10.  Renal Protective Effect of Everolimus in Liver Transplantation: A Prospective Randomized Open-Label Trial.

Authors:  Zakiyah Kadry; Jonathan G Stine; Takehiko Dohi; Ashokkumar Jain; Kimberly L Robyak; Osun Kwon; Christopher J Hamilton; Piotr Janicki; Thomas R Riley; Fauzia Butt; Karen Krok; Ian R Schreibman; Dmitri Bezinover; Nasrollah Ghahramani; Stalin Campos; Christopher S Hollenbeak
Journal:  Transplant Direct       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.